Digestive Disease Associates, PA

Baltimore, Maryland 21229

0 studies enrolling now · 20 studies all time

What they study most

Chronic HBV Infection, Chronic Hepatitis B, Chronic Hepatitis C, Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, Digestive System Diseases, Helicobacter Pylori Infection, Hepatitis B, Chronic, Hepatitis C, Hepatitis C Virus, Hepatitis C, Chronic

Studies at this site

• Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori — Completed
• Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B — Completed
• Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection — Stopped early
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis — Completed
• Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection — Completed
• Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer — Completed
• Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies — Completed
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Ph IIA Study (SOC +/- NS5B) — Completed
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV — Completed
• Phase 3 Study of Sofosbuvir and Ribavirin — Completed
• Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B — Completed